Pharmaceutical News RSS Feed - Pharmaceutical News

VisiVite reports upcoming release of ProVision macular health formula

VisiVite reports upcoming release of ProVision macular health formula

VisiVite, a world leader in ocular nutrition, today announced its upcoming January 2015 release of ProVision, a professional macular health formula designed to be easy for eye doctors to dispense and affordable for their patients to use. [More]
Study unveils genetic architecture that enables parasite to develop antimalarial drug resistance

Study unveils genetic architecture that enables parasite to develop antimalarial drug resistance

The largest genome-wide association study to date of the malaria parasite Plasmodium falciparum unveils a complex genetic architecture that enables the parasite to develop resistance to our most effective antimalarial drug, artemisinin. The results could help to improve early detection of emerging artemisinin resistance. [More]
AMRI awarded NIH contract for drug development services

AMRI awarded NIH contract for drug development services

AMRI today announced it received a 10-year federal contract award from the National Institutes of Health for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke award will support NIH's Drug Manufacturing and Formulation Program (DMFP), which is a component of the Blueprint Neurotherapeutics Network (BPN). [More]
BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.R.L Grants The Exclusive Distribution Rights For Gelx® Oral Gel And Gelx® Spray For The Treatment Of Oral Mucositis In Cancer Patients To FERRER INTERNACIONAL S.A.

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with FERRER INTERNACIONAL S.A., granting them the rights to promote, sell and market its own product GelX for the Middle East, Eastern Europe, Russia and North Africa. [More]
Researchers identify clusters of underimmunization, vaccine refusal in Northern California

Researchers identify clusters of underimmunization, vaccine refusal in Northern California

Researchers used spatial analysis software and electronic medical records to identify clusters of underimmunization and vaccine refusal among Kaiser Permanente members in Northern California, according to a study published today in the journal Pediatrics. [More]
Almost 42% of US drinkers use alcohol-interactive prescription medications, study finds

Almost 42% of US drinkers use alcohol-interactive prescription medications, study finds

Approximately 71 percent of American adults drink alcohol. While alcohol interacts negatively with a number of commonly prescribed medications, little is known on a population level about the use of alcohol-interactive (AI) prescription medication among US drinkers. A new study has found that almost 42 percent of drinkers in the US population have used one or more alcohol-interactive prescription medications. [More]
Solvanix set up to commercialise novel antibody-stabilisation technology

Solvanix set up to commercialise novel antibody-stabilisation technology

The Garvan Institute of Medical Research announces the launch of spin-off company Solvanix Pty Ltd, set up to commercialise a novel technology that will improve the stability of therapeutic monoclonal antibodies. [More]
FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States. [More]
Researchers reveal how melanoma becomes resistant to promising new drug combo therapy

Researchers reveal how melanoma becomes resistant to promising new drug combo therapy

In a new study led by UCLA Jonsson Comprehensive Cancer Center member Dr. Roger Lo, researchers have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage. [More]
Study: Century-old drug may help treat autism

Study: Century-old drug may help treat autism

Autism spectrum disorders (ASD) affect 1 to 2 percent of children in the United States. Hundreds of genetic and environmental factors have been shown to increase the risk of ASD. Researchers at UC San Diego School of Medicine previously reported that a drug used for almost a century to treat trypanosomiasis, or sleeping sickness, reversed environmental autism-like symptoms in mice. [More]
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. [More]
Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for prescribing drugs to manage obesity and promote weight loss. [More]
Report: Folic acid saves babies from neural tube defects

Report: Folic acid saves babies from neural tube defects

Fortifying grain foods with the B vitamin folic acid has saved about 1,300 babies every year from being born with serious birth defects of the brain and spine known as neural tube defects (NTDs), according to new data published by the US Centers for Disease Control and Prevention in its publication Morbidity and Mortality Weekly Report. [More]
New study finds no correlation between opioids administered in the ER and patient satisfaction scores

New study finds no correlation between opioids administered in the ER and patient satisfaction scores

A new study co-authored by investigators at the University of Massachusetts Medical School found that there is no correlation between opioids administered in the emergency room setting and Press Ganey ED patient satisfaction scores, one of the most commonly used metrics for measuring patient satisfaction. [More]
MRIGlobal awarded $54 million NIH contract to provide support for drug development

MRIGlobal awarded $54 million NIH contract to provide support for drug development

MRIGlobal today announced that it has been awarded a $54 million, 10-year program from the National Institute of Neurological Disorders and Stroke to provide support for the development and manufacturing of drug candidates for ultimate use in human clinical trials. [More]
China Jo-Jo Drugstores opens eight new retail pharmacies in Hangzhou

China Jo-Jo Drugstores opens eight new retail pharmacies in Hangzhou

China Jo-Jo Drugstores, Inc., a leading China-based retail and wholesale distributor of pharmaceutical and health care products through its own online and retail pharmacies, announced today that it opened eight new retail pharmacies in Hangzhou on January 10, 2015, a company record for same-day store openings. [More]
Endocrinology Network offers up-to-date coverage of SGLT2 inhibitors

Endocrinology Network offers up-to-date coverage of SGLT2 inhibitors

UBM Medica US announces that Endocrinology Network, a leading online community for endocrinologists and other clinicians who treat patients with T2DM offers comprehensive and up-to-date coverage of the sodium glucose cotransporter 2 (SGLT2) inhibitors. [More]
BellBrook Labs announces launch of new Transcreener UDP TR-FRET Assay

BellBrook Labs announces launch of new Transcreener UDP TR-FRET Assay

BellBrook Labs, a leader in high throughput screening assays for drug discovery, announced the launch of a TR-FRET (time resolved Forster resonance energy transfer) version of the company's Transcreener UDP Assay, a high throughput screening assay for glycosyltransferases and other UDP-producing enzymes. [More]
Scientists identify first genetic marker linked to severe neurological toxicity

Scientists identify first genetic marker linked to severe neurological toxicity

Paclitaxel is a chemotherapeutic drug that has been shown to be highly effective when treating solid tumours, such as breast, ovarian and lung tumours. However, its use frequently causes peripheral neuropathies, neurological problems that affect the vast majority of patients. [More]
GSU researchers discover how steroids use a novel 'trick' to suppress inflammation

GSU researchers discover how steroids use a novel 'trick' to suppress inflammation

A new "trick" steroids use to suppress inflammation, which could be used to make new anti-inflammatory drugs without the harmful side effects of steroids, has been discovered by researchers at Georgia State University. [More]